Proof-of-concept Studies For A Novel Anti-thrombotic Agent
Funder
National Health and Medical Research Council
Funding Amount
$632,352.00
Summary
Blood clots cause most heart attacks and strokes, and platelets are the blood cells that form these clots. Drugs that block platelet function, such as aspirin, are used to prevent heart attack and stroke but are frequently ineffective. Here, we will develop a new drug that prevents platelet incorporation into blood clots, that will be suitable for the prevention of heart attack and stroke in humans, and that may improve on existing therapies.
Development Of CD96 Antibodies For Cancer Treatment
Funder
National Health and Medical Research Council
Funding Amount
$820,821.00
Summary
There is an unmet medical need to develop new immunotherapies that are safer and potentially allow the treatment of a broader range of cancers. Inhibiting the immune checkpoint CD96 function represents an opportunity that may parallel and indeed complement the activity and impact of other lymphocyte checkpoint inhibitors in human cancer (eg. CTLA-4 and PD1/PD-L1). While developing a new human therapeutic antibody we will also learn more about an important checkpoint in the immune response.
Humanisation And Pre-clinical Validation Of A Therapeutic Anti-cancer Antibody
Funder
National Health and Medical Research Council
Funding Amount
$699,136.00
Summary
This grant will develop a novel antibody against a protease expressed on cancer cells. Preclinical studies, and antibody humanisation, will be performed. This project will also provide vital information on optimal therapeutic approaches with the antibody that can be ultimately taken into human trials.